Who
Nathan L. Mata
Chief Scientific Officer
Company insider
Files Form 4 as: Chief Scientific Officer, Belite Bio.
In numbers
- Trades disclosed
- 208
- Buys
- 0
- Sells
- 17
- Bought
- $0
- Sold
- $5.3M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 31 Mar 2026
- Last trade
- 7 May 2026
- Last filed
- 8 May 2026
Companies traded
Activity over time
1 Apr – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 7 May 2026filed 8 May 2026 | BLTE Belite BioBiotechnology | SEC FORM 4 Sold | $34K226 at $152.45 | filing |
| 7 May 2026filed 8 May 2026 | BLTE Belite BioBiotechnology | SEC FORM 4 Sold | $66K428 at $153.56 | filing |
| 7 May 2026filed 8 May 2026 | BLTE Belite BioBiotechnology | SEC FORM 4 Sold | $4643 at $154.61 | filing |
| 7 May 2026filed 8 May 2026 | BLTE Belite BioBiotechnology | SEC FORM 4 Sold | $1,3979 at $155.25 | filing |
| 7 May 2026filed 8 May 2026 | BLTE Belite BioBiotechnology | SEC FORM 4 Sold | $34K226 at $152.45 | filing |
| 7 May 2026filed 8 May 2026 | BLTE Belite BioBiotechnology | SEC FORM 4 Sold | $66K428 at $153.56 | filing |
| 7 May 2026filed 8 May 2026 | BLTE Belite BioBiotechnology | SEC FORM 4 Sold | $4643 at $154.61 | filing |
| 7 May 2026filed 8 May 2026 | BLTE Belite BioBiotechnology | SEC FORM 4 Sold | $1,3979 at $155.25 | filing |
| 6 May 2026filed 7 May 2026 | BLTE Belite BioBiotechnology | SEC FORM 4 Sold | $1,2138 at $151.57 | filing |
| 6 May 2026filed 7 May 2026 | BLTE Belite BioBiotechnology | SEC FORM 4 Sold | $65K424 at $152.67 | filing |
| 6 May 2026filed 7 May 2026 | BLTE Belite BioBiotechnology | SEC FORM 4 Sold | $20K128 at $153.42 | filing |
| 6 May 2026filed 7 May 2026 | BLTE Belite BioBiotechnology | SEC FORM 4 Sold | $37K240 at $154.41 | filing |
| 6 May 2026filed 7 May 2026 | BLTE Belite BioBiotechnology | SEC FORM 4 Sold | $16K100 at $155.97 | filing |
| 6 May 2026filed 7 May 2026 | BLTE Belite BioBiotechnology | SEC FORM 4 Sold | $16K100 at $156.00 | filing |
| 6 May 2026filed 7 May 2026 | BLTE Belite BioBiotechnology | SEC FORM 4 Sold | $1,2138 at $151.57 | filing |
| 6 May 2026filed 7 May 2026 | BLTE Belite BioBiotechnology | SEC FORM 4 Sold | $65K424 at $152.67 | filing |
| 6 May 2026filed 7 May 2026 | BLTE Belite BioBiotechnology | SEC FORM 4 Sold | $20K128 at $153.42 | filing |
| 6 May 2026filed 7 May 2026 | BLTE Belite BioBiotechnology | SEC FORM 4 Sold | $37K240 at $154.41 | filing |
| 6 May 2026filed 7 May 2026 | BLTE Belite BioBiotechnology | SEC FORM 4 Sold | $16K100 at $155.97 | filing |
| 6 May 2026filed 7 May 2026 | BLTE Belite BioBiotechnology | SEC FORM 4 Sold | $16K100 at $156.00 | filing |
News
Belite Bio (NASDAQ:BLTE) Insider Hendrik Peter Scholl Sells 500 Shares of Company StockBLTE · themarketsdaily.com · 6 Oct 2026Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Stock Has Average Target Price of $218.73BLTE · dailypolitical.com · 5 Oct 2026
0 headlines in the last 90 days name Nathan L. Mata; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.